UPDATE -- Biovie Inc. Announces Pricing Of Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

( MENAFN - GlobeNewsWire - Nasdaq) CARSON CITY, Nev., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioVie Inc.

(NASDAQ: BIVI), (“BioVie” or the“Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a registered direct offering of 1,146,000 shares of its common stock priced at-the-market under nasdaq rules at a price of $2.83 per share, resulting in total gross proceeds of approximately $3.2 million, before deducting the placement agent's fees and offering expenses.

The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. All of the shares of common stock are being offered by the Company. The registered direct offering is expected to close on or about October 29, 2024, subject to the satisfaction of customary closing conditions.

ThinkEquity is acting as sole placement agent for the offering. The securities were offered and will be sold pursuant to a shelf registration statement on Form S-3 (File No. 333-274083), including a base prospectus, filed with the U.

S. Securities and Exchange Commission (the“SEC”) on August 18, 2023 and declared effective on August 28, 2023. The offering will be made only by means of a written prospectus.

A final prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the S.